Xponance Inc. Decreases Stock Holdings in Danaher Corporation $DHR

Xponance Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 3.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 97,789 shares of the conglomerate’s stock after selling 3,016 shares during the period. Xponance Inc.’s holdings in Danaher were worth $19,388,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. WFA of San Diego LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $26,000. Howard Hughes Medical Institute bought a new position in shares of Danaher during the second quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in Danaher in the third quarter worth $27,000. TruNorth Capital Management LLC purchased a new position in Danaher during the 3rd quarter valued at $28,000. Finally, Tripletail Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth $31,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of DHR opened at $209.35 on Friday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $242.80. The company has a market capitalization of $148.04 billion, a P/E ratio of 41.54, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. The firm has a 50 day moving average of $225.62 and a 200 day moving average of $216.09. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, beating the consensus estimate of $2.14 by $0.09. The business had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The company’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the business posted $2.14 EPS. As a group, equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.40 per share. The ex-dividend date is Friday, March 27th. This represents a $1.60 annualized dividend and a yield of 0.8%. This is an increase from Danaher’s previous quarterly dividend of $0.32. Danaher’s dividend payout ratio (DPR) is currently 31.75%.

Insider Activity

In other news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the sale, the executive vice president directly owned 5,099 shares in the company, valued at $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Wells Fargo & Company boosted their price target on shares of Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Danaher in a report on Thursday, January 29th. Weiss Ratings restated a “hold (c)” rating on shares of Danaher in a research note on Monday, December 29th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Finally, HSBC increased their price objective on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $253.86.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.